In this Review, we provide an up-to-date overview on the use of P2Y12 inhibitor monotherapy after PCI, including supporting pharmacodynamic and clinical evidence, practical recommendations and future directions. https://t.co/pVWJys5pl1
Impressive sustained BP lowering results of renal denervation through 3 years in the sham-controlled SPYRAL HTN-ON MED trial, published in Lancet. This 10 mmHg difference in ABPM would be expected to translate to substantial cardiovascular benefits.
The ARC-HBR definition identifies about 40% of PCI patients at higher risk of major bleedings and other potentially harmful events. These are the most common major and minor criteria that justify the HBR status in daily practice. #ACC22
🚨 Hot topic: Post-PCI physiology at next Journal Club
Join @AndreaMarrone3 and our expert @Tebaldi_Matteo to discuss the #DEFINE PCI study:
📍 Post-PCI iFR
📍 Residual ischemia
📍 1yr clinical outcomes
🗓 Fri 4th Mar
🕰 7.30-8.00 am (Rome)
➡️ DM for Zoom link